Kailera appoints Kathleen Tregoning as chief corporate affairs officer

US clinical-stage biotech Kailera Therapeutics (Nasdaq: KLRA), which is focused on elevating the next era of obesity care, has announced the appointment of Kathleen Tregoning as chief corporate affairs officer.

“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, president and chief executive of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new options to people living with obesity,” he noted.